Close
Close

Tumor Target Specific Antibody Discovery Service by Premade Library

Screening Services Workflow Premade Libraries Cases Related Services Why Choose Us? FAQ

Facing compressed timelines and challenging tumor antigens? Creative Biolabs delivers a decisive advantage with our industry-leading premade antibody library platform. We offer the streamlined discovery engine designed to identify high-affinity, functional antibodies against a diverse spectrum of tumor-specific targets.

Get Started Now. Request Your Free Quote.

Anti-Tumor-Specific Target Antibody Discovery

Targeting Tumor-Specific Antigens (TSAs) and Tumor-Associated Antigens (TAAs) remains the cornerstone of modern oncology. However, traditional immunization methods often encounter significant hurdles, such as immune tolerance, low immunogenicity, or the inherent toxicity of certain tumor antigens. At Creative Biolabs, we bypass these biological bottlenecks to accelerate your oncology pipeline with precision and speed.

By harnessing our proprietary, hyper-diverse premade antibody libraries (1011 diversity), we facilitate the rapid isolation of high-affinity, high-specificity antibodies against even the most elusive tumor targets. Our service transcends basic binding assays, providing a sophisticated discovery platform that prioritizes functional performance from the very beginning.

Your Perfect Solution Awaits. Request a Quote.

Workflow

Our screening services use state-of-the-art phage display and yeast display technologies to identify high-affinity, tumor-specific antibodies with the precision your research demands. We employ a negative selection strategy to deplete binders to normal tissues, ensuring your leads interact exclusively with the tumor phenotype.

  • Fig.1 Antigen Preparation. (Creative Biolabs AI)
    Antigen Preparation

    QC of recombinant protein, peptide, or over-expressing cell lines. Biotinylation/immobilization validation.

  • Fig.2 Library Panning. (Creative Biolabs AI)
    Library Panning

    3-4 rounds of biopanning. Stringency modulation (washing/off-rate selection). Negative selection against healthy cells.

  • Fig.3 Screening & Validation. (Creative Biolabs AI)
    Screening & Validation

    High-throughput ELISA/FACS screening of monoclonals. Sequencing of positive hits.

  • Fig.4 Functional Validation. (Creative Biolabs AI)
    Functional Validation

    Full characterization of top candidates (affinity, specificity, etc.) and validation using functional assays (e.g., cell-based assays)

  • Fig.5 Pilot Production & Bioactivity Validation. (Creative Biolabs AI)
    Pilot Production & Bioactivity Validation

    Transient expression to produce purified IgG or antibody fragments (scFv/Fab) for preliminary evaluation.

Need Pricing? Reach Out for a Quick Quote

Ready-to-Screen Antibody Libraries

We offer a variety of premade antibody libraries, each with distinct features tailored for anti-tumor target discovery. Explore our diverse options below to select the right library for your research needs.

Human Camel Llama Alpaca Humanized VHH
Antibody Library ID Display Technology Library Format Library Size
HuScL-6
☆Highly Recommended 		pIII-fusion, Phagemid Phage Display Naïve scFv 2.1×1011
HuScL-3S pIII-fusion, Phagemid Phage Display Semi-synthetic scFv >1.0×1011
HuFabL-4 pIII-fusion, Phagemid Phage Display Naïve Fab 1.9×1010
HuFabssL-1 pIII-fusion, Phagemid Phage Display Naïve & synthetic Fab 1.8×1010

Find the Perfect Library for Your Target

Case Study: High-Diversity Libraries, High-Impact Outcomes

Precision Epitope-Targeted Discovery of Anti-Tumor scFv Antibodies
Objective In the competitive landscape of oncology drug development, identifying new antibody leads that bind to a validated clinical epitope is a high-value strategy. Whether the goal is to replicate a successful Mechanism of Action (MOA) or to develop a biosimilar/bio-better, the ability to target a specific site on a tumor antigen is essential.
Competitive Epitope-Specific Selection To isolate antibodies with the exact binding profile required, we utilized a high-pressure Competitive Elution strategy. This ensures that the recovered clones are not just target-binders, but specifically epitope-competitors.
  • Materials: * Antigen: Target-huFc fusion protein. * Control: huFc protein (to eliminate Fc-region binders).
  • Benchmark: An established Positive Antibody (Reference).
  • Library: High-diversity Premade Human scFv (Single-chain Variable Fragment) Library.
Precision Screening Workflow:
  • Rigorous Counter Selection
The library was pre-incubated with control huFc protein to deplete any non-specific binders to the Fc tag.
  • Positive Selection
Specific binders were captured using biotinylated Target-huFc.
  • Directed Competitive Elution
Instead of a general buffer elution, we used an excess of the Positive Antibody to competitively displace and release only those scFv phages that bind to the identical epitope.
Key Results & Validation 1. High-Efficiency Enrichment
Through four rounds of iterative panning and competitive pressure, the phage output showed significant enrichment. This indicated a successful convergence of the library toward the specific epitope of interest.

Fig.6 Graph illustrating the library screening outcomes. (Creative Biolabs Original)

Fig.7 Graph displaying the phage ELISA validation results. (Creative Biolabs Original)

2. Orthogonal Epitope Confirmation
Initial screening identified eight high-affinity candidates. To confirm their binding site, we performed a Competitive Soluble scFv ELISA.

Fig.8 Graph displaying the binding validation results. (Creative Biolabs Original)

Fig.9 Graph displaying the functional validation results. (Creative Biolabs Original)

  • 5 lead candidates demonstrated significant competitive binding against the reference antibody.
  • The sequences of these verified epitope-specific antibodies were delivered to the client for downstream functional characterization and MOA replication.

Explore Your Options. Request a Quote.

Related Services

Fig.10 Anti-Disease-specific Target Antibody Discovery. (Creative Biolabs Authorized)

Anti-infectious disease-specific Antibody Discovery

Anti-inflammation disease-specific Antibody Discovery

Anti-autoimmune disorder-specific Antibody Discovery

Anti-allograft rejection-specific Antibody Discovery

Why Choose Us?

Diverse Target Interrogation

We specialize in discovering antibodies against a wide array of targets. This includes everything from well-characterized solid tumor surface markers to checkpoint inhibitors and the more elusive components hidden within the Tumor Microenvironment (TME).

Success with Novel and Recalcitrant Targets

Our platform is specifically engineered to unlock undruggable or novel targets where conventional methods typically fail. This capability provides you with a distinct strategic advantage in highly competitive therapeutic areas.

Bespoke Screening Strategies

We believe that every project is unique. Our experts design customized screening cascades that incorporate cell-based panning and functional assays, ensuring the process is perfectly tailored to your specific tumor indication and biological requirements.

Developability-First Engineering

Every lead we isolate is pre-validated for its clinical potential. We prioritize clones that demonstrate superior stability, low immunogenicity, and optimal CMC profiles to ensure a seamless transition from discovery to large-scale manufacturing.

Customize Your Package - Get Pricing

Ready to move fast? Creative Biolabs will scope your target, advise on best library and protocol, and get screening up and running as soon as possible.

FAQ

  1. What are the key advantages of using a Premade Library over immunized libraries?

    Our Premade Phage & Yeast Display Libraries offer a significant time-to-market advantage. Since the libraries are already constructed with high diversity (up to 1011 variants), we can skip the 3-4 month animal immunization phase. This allows us to identify high-affinity lead candidates in as little as 4-6 weeks, making it ideal for competitive tumor-target drug discovery.

  2. How do you ensure the library can recognize "difficult" or "novel" tumor antigens?

    Our libraries are engineered for maximum structural diversity, incorporating synthetic or semi-synthetic human antibody frameworks. This high diversity ensures a high probability of finding binders even for: Highly conserved antigens (where animal immunization often fails due to immune tolerance). Conformational epitopes of complex membrane proteins (e.g., GPCRs or Ion Channels). Toxic or unstable antigens that cannot be used in vivo.

  3. Can I choose the specific antibody format for the screening?

    Yes. While the initial screening is typically performed in VHH, scFv or Fab formats, we offer seamless conversion to Full-length IgG (Human or Chimeric), or even Bi-specific formats. Our yeast display platform is particularly effective for fine-tuning the stability and expression levels of the final therapeutic format.

  4. What information is required to initiate a project?

    To provide you with an accurate quote and timeline, we simply need: Target Information: The protein sequence, accession number, or specific cell line. Desired Format: (e.g., Human IgG1, scFv, etc.). Application Goal: (e.g., ADC development, CAR-T scFv, or Neutralizing antibody).


All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

Related Sections
Online Inquiry
CONTACT US
USA:
Europe:
Germany:
Call us at:
USA:
UK:
Germany:
Fax:
Email:
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us
© 2026 Creative Biolabs. | Contact Us